Search Results - frank+schoenen

3 Results Sort By:
Heterocyclic Compounds for the Treatment of Hepatitis C Virus
The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the...
Published: 7/25/2024   |   Inventor(s): Zongyi Hu, Juan Marugan, Noel Southall, Xin Hu, Jingbo Xiao, Shanshan (Melissa) He, Marc Ferrer-Alegre, Wei Zheng, Kevin Frankowski, Frank Schoenen, Kelin Li, Tsanyang (Jake) Liang
Keywords(s): C, Class, compounds, DB4BXX, Development, Hepatitis, Novel, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease
Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies
Gaucher disease is a rare lysosomal storage disease that is characterized by a loss of function of the glucocerebrosidase (GCase) enzyme, which results in a decreased ability to degrade its lipid substrate, glucocerebroside. The intracellular build up of this lipid causes a broad range of clinical manifestations, ranging from enlarged spleen/liver...
Published: 7/25/2024   |   Inventor(s): Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Steven Rogers, Frank Schoenen, Juan Marugan
Keywords(s): CHAPERONES, Gaucher Disease, GLUCOCEREBROSIDASE, IBXXXX, NB1BXX, NBXXXX, NON-INHIBITORY, Parkinson's Disease, proteinopathy, UAXXXX, VEXXXX, WKXXXX, YAXXXX, YBXXXX
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Rare / Neglected Diseases
Small molecule inhibitors of the mitochondrial permeability transition pore (PTP)
Summary Dysfunction of the mitochondrial permeability transition pore (mtPTP) is associated with accumulation of reactive oxygen species (ROS) in many disease states. Researchers at Oregon Health & Science University, University of Kansas, and University of Padova have developed highly potent and stable small molecule inhibitors of mtPTP. Technology...
Published: 9/23/2022   |   Inventor(s): Michael Forte, Dennis Bourdette, Paolo Bernardi, Justina Sileikyte, Frank Schoenen, Sudeshna Roy
Keywords(s): Therapeutics, Therapeutics - Cardiology, Therapeutics - Neurology
Category(s): Therapeutics